Brief Introduction of Chairman - Prof. Isa Odidi

From 1995 to 1998, Prof. Odidi served as the Vice President and Chief Scientific Officer of the world-renowned pharmaceutical company Biovail (now Bausch Health Companies, ranked 31st in the world's top 50 pharmaceutical companies in 2019). He filed the first ANDA application for a generic controlled release drug with FDA and the first NDA application for a controlled release drug under 505B(2) pathway in Canadian history.

Prof. Odidi has developed a number of proprietary drug delivery technology platforms with extended-release, controlled-release, timed-release, and targeted-release capabilities, and successfully invented dozens of drugs, including improved new drugs and difficult genericised controlled release drugs. Among them, Prof. Odidi has developed more than a dozen drugs exclusively for Biovail and signed BD contracts with a number of Fortune 50 pharmaceutical companies to have the products marketed and sold in 55 countries. In 1997, TEVA and Biovail worked on a number of controlled-release generic drugs together. Prof. Odidi successfully invented three blockbuster generic drugs that were first in the market, which achieved significant success in the US market, bringing over US$100 million in net sales to Biovail every year. The successful launch of a range of drugs by Prof. Odidi helped Biovail grow from a start-up R&D company to the largest controlled drug release pharmaceutical company in North America. With annual sale of over US$1 billion, it became the largest listed pharmaceutical company in Canada, with a market capitalization of over US$10 billion.

Prof. Odidi has hundreds of patents approved in countries such as the United States, Canada, EU, China, Japan and India. There are more than 200 patents worldwide cited from Prof. Odidi’s technology.